Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

June 17, 2025 by Alan Khadavi

Tezspire for Nasal Polyps: A New Targeted Therapy on the Horizon

As allergists, we are increasingly managing patients with chronic rhinosinusitis with nasal polyps (CRSwNP)—a condition driven by Type 2 inflammation that often coexists with asthma, aspirin-exacerbated respiratory disease (AERD), and allergic rhinitis. While Dupilumab has been a major breakthrough, we continue to see a subset of patients with suboptimal responses or contraindications to currently approved biologics.

Tezepelumab (Tezspire®), a monoclonal antibody targeting TSLP (thymic stromal lymphopoietin), offers a novel upstream mechanism that may expand our treatment arsenal for nasal polyposis.


The Role of TSLP in Type 2 Inflammation

TSLP is an epithelial-derived alarmin released in response to environmental and inflammatory triggers. It acts on multiple downstream pathways by activating dendritic cells, innate lymphoid cells (ILC2s), and promoting the differentiation of Th2 cells—thereby orchestrating the release of IL-4, IL-5, and IL-13.

This upstream activation makes TSLP a strategic target in polymorphic Type 2 conditions, such as:

  • Severe eosinophilic asthma

  • Nasal polyposis

  • Atopic dermatitis

  • Eosinophilic esophagitis

By blocking TSLP, tezepelumab inhibits both adaptive and innate Type 2 pathways, distinguishing it mechanistically from agents targeting IL-4Rα (Dupixent), IL-5 (Nucala, Fasenra), or IgE (Xolair).


Tezspire in CRSwNP: Clinical Evidence

While tezepelumab is currently FDA-approved for severe asthma, it is now being evaluated in Phase 3 trials for CRSwNP (e.g., the WAYPOINT study, NCT05553090).

Key endpoints include:

  • Change in nasal polyp score (NPS)

  • Lund-Mackay CT scores

  • Improvement in nasal congestion scores and sense of smell

  • Reduction in systemic corticosteroid use and surgical rescue rates

Early results from asthma trials (e.g., NAVIGATOR) have shown significant reductions in blood and sputum eosinophils, FeNO, and asthma exacerbation rates, regardless of baseline eosinophil count—suggesting potential benefit for patients with low eosinophil CRSwNP phenotypes as well.


Potential Role in Refractory Nasal Polyposis

As specialists, we encounter patients who:

  • Fail to respond adequately to Dupilumab

  • Experience adverse effects or contraindications to existing biologics

  • Have mixed inflammatory endotypes or uncertain biomarkers

Tezepelumab’s broader suppression of the inflammatory cascade makes it an intriguing candidate for such cases. Its mechanism may address both eosinophilic and non-eosinophilic CRSwNP endotypes, potentially offering improved outcomes in a wider population.


Administration and Practical Considerations

Tezspire is administered as a subcutaneous injection every 4 weeks, and is currently only available for healthcare professional administration, though at-home injection protocols are under evaluation.

As with other biologics, long-term safety, adherence, cost, and insurance coverage will be key considerations should it be approved for CRSwNP.


Conclusion

Tezepelumab represents a promising biologic that may shift our paradigm for treating nasal polyps—particularly in refractory, non-traditional, or steroid-dependent patients. As the results of ongoing trials emerge, we may soon have another evidence-based option that targets airway inflammation from its origin.

As always, patient selection, phenotype characterization, and biomarker profiling will be essential to integrating Tezspire effectively into clinical practice.

Tezspire Tezepelumab for Severe Asthma

Nasal Polyps Treatment; Past, Present and Future

Best Nasal Polyps Treatment


Dr. Alan Khadavi is a board-certified allergist and immunologist based in Los Angeles, specializing in the diagnosis and treatment of chronic sinus disease, asthma, and allergic conditions.

Filed Under: Blog, nasal polyps

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page